Further, the authors showed that the RGMa-mAb had a beneficial effect on both AQP4-IgG-induced astrocytopathy and motor deficits, as well as neuropathic pain, in NMO rats [13]. This evidence concerns the gene AQP4 and neuromyelitis optica.